Skip to content

Author

E. Rossokha

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy of alectinib in advanced ALK-positive non-small cell lung cancer: Results from the Russian multicenter KARL-005 study

Introduction. Tyrosine kinase inhibitors, specifically alectinib, have significantly improved the prognosis for patients with advanced ALK-positive non-small cell lung cancer (ALK+ aNSCLC). National multicenter real-world data are essential to validate these outcomes within a broader clinical population. Aim....

D. Marinov, D. Perunov, L. Nefedova et al. · 0 citations
Open access Sep 2026

The RATIONALE study: Outcomes of targeted therapy for metastatic melanoma in Russia

In real-world clinical practice, BRAF/MEK targeted therapy has demonstrated effectiveness in the Russian patient population, with outcomes consistent with those observed in randomized clinical trials, despite substantial population heterogeneity and the inclusion of patients with unfavorable prognostic factors.

I. Samoylenko, K. Orlova, N. V. Leushina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.